 |
Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Nov 27, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events ...
|
|
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Nov 27, 2012
|
18.7 KB |
|
| |
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). According to the European Medicines Agency (EMA) approv...
|
|
ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
Nov 16, 2012
|
24.3 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Nov. 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ...
|
|
Regeneron Announces November 2012 Investor Conference Presentations
Nov 6, 2012
|
9.7 KB |
|
| |
TARRYTOWN, N.Y., Nov. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Lazard Capital Markets 9th Annual Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday, November 13, 2012
Credit Suisse Healthcare Conference at 9:30 a.m. Eas...
|
|
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Nov 5, 2012
|
21.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients. SAR236553/REGN727 is an investigational subcutaneously adm...
|
|
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Oct 31, 2012
|
19.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Oct. 31, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.
...
|
|
Regeneron Reports Third Quarter 2012 Financial and Operating Results
Oct 24, 2012
|
30.9 KB |
|
| |
TARRYTOWN, N.Y., Oct. 24, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial and operating results for the third quarter of 2012 and provided an update on development programs.
The Company reported total revenues of $428 million in the third quarter and $964 million in the first nine months of 2012...
|
|
Regeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Oct 18, 2012
|
18.3 KB |
|
| |
TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://dig...
|
|
Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Oct 10, 2012
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Oct. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2012 financial and operating results on Wednesday, October 24, 2012, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day.
...
|
|
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Sep 28, 2012
|
19.9 KB |
|
| |
TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA trea...
|
|
Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Sep 21, 2012
|
18.3 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO). The recommended dose for EYLEA is 2 milligrams (mg) ever...
|
|
Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Sep 21, 2012
|
10.8 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey.
"This recognition by Science as the most respected company to work for in the bioph...
|
|
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Sep 21, 2012
|
18.5 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AM...
|
|
Regeneron Announces September 2012 Investor Conference Presentations
Aug 29, 2012
|
9.7 KB |
|
| |
TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Tim...
|
|
U.S. FDA Approves ZALTRAP® (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer
Aug 3, 2012
|
76.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Aug. 3, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLF...
|
|
Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Jul 30, 2012
|
13.4 KB |
|
| |
TARRYTOWN, N.Y., July 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the supplemental biologics license application (sBLA) for ARCALYST® (rilonacept) Injection for Subcutaneous Use for the prevention of gout flares in...
|
|
Regeneron Reports Second Quarter 2012 Financial and Operating Results
Jul 25, 2012
|
29.8 KB |
|
| |
TARRYTOWN, N.Y., July 25, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the second quarter of 2012 and provided an update on development programs.
The Company reported total revenues of $304 million in the second quarter and $536 million in the first half of 2012. T...
|
|
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Jul 20, 2012
|
22.2 KB |
|
| |
PARIS and TARRYTOWN, New York, July 20, 2012 /PRNewswire/ --
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment. SAR236553/REGN727 is a potential first-in-class, subcut...
|
|
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Jul 11, 2012
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EDT that day.
Live audio of the con...
|
|
Regeneron Announces June 2012 Investor Conference Presentations
May 30, 2012
|
9.8 KB |
|
| |
TARRYTOWN, N.Y., May 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Goldman Sachs Global Healthcare Conference 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on Tuesday, June 5, 2012
Jefferies 2012 Global Healthcare Conferen...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds